Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a late-stage biopharmaceutical company focused on central nervous system (CNS), inflammatory, and cardiometabolic diseases. The RVPH news feed highlights the company’s progress in advancing its pipeline, particularly its lead candidate brilaroxazine (RP5063), which is being developed for schizophrenia and explored for additional indications such as pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF).
News updates commonly cover clinical trial milestones, including data from the Phase 3 RECOVER program in schizophrenia and its 1-year open-label extension. Reviva has reported broad-spectrum efficacy across major symptom domains, reductions in proinflammatory cytokines, and long-term safety and tolerability data for brilaroxazine. The company also releases information on biomarker research, such as vocal biomarker analyses that use speech latency to characterize negative symptoms and enrich antipsychotic clinical trials.
Regulatory and corporate developments are another key theme in RVPH news. Investors can follow announcements related to FDA interactions, including pre-New Drug Application (pre-NDA) feedback recommending a second Phase 3 trial in schizophrenia, as well as plans for the RECOVER-2 registrational study, subject to financing. Updates on Orphan Drug Designation for PAH and IPF, European patent grants for pulmonary fibrosis, and broader intellectual property strategy are also featured.
In addition, the news flow includes participation in scientific meetings, investor conferences, and key opinion leader events, where Reviva presents clinical and mechanistic data on brilaroxazine. For market participants tracking RVPH stock, this page consolidates company-issued press releases on clinical data, regulatory guidance, financing transactions, and strategic presentations in one place.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) will host a webinar on May 2, 2023, at 11:00 AM ET featuring KOL Larry Ereshefsky, PharmD, discussing brilaroxazine (RP5063), a serotonin-dopamine modulator in late development for schizophrenia. The event will cover the unmet medical need in schizophrenia treatment and Reviva's clinical trial data, including the ongoing RECOVER Phase 3 trial. Brilaroxazine has exhibited significant efficacy in a Phase 2 study, demonstrating improvements in PANSS total scores and meeting safety endpoints. Furthermore, it has potential for use in other neuropsychiatric and pulmonary conditions, having received Orphan Drug Designation from the FDA for certain indications. This webinar aims to provide insights on the treatment landscape and sustainable advancements in psychiatric and inflammatory therapies.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will present a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry from April 27-29, 2023, in San Diego, CA. The presentation, titled "Brilaroxazine (RP5063), a novel serotonin-dopamine stabilizer, displays antipsychotic efficacy in rodents," will take place on April 29, 2023, from 5:00-7:00 PM PT.
Brilaroxazine is a drug candidate showing significant clinical promise for treating schizophrenia and related disorders. In Phase 2 studies, it met primary endpoints, demonstrating efficacy with no adverse effects on weight or metabolic parameters. Additionally, it has potential applications in pulmonary diseases like PAH and IPF, having received Orphan Drug Designation from the FDA. Reviva aims to pursue further development of brilaroxazine for various neuropsychiatric conditions.
FAQ
What is the current stock price of Reviva Pharmaceutcls Hldgs (RVPH)?
What is the market cap of Reviva Pharmaceutcls Hldgs (RVPH)?
